FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

OMB APPROVAL

(Street) **BOSTON**

MA

02116

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or fritten plan for

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

							2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) 200 BER	•	First) ΓREET, 18TH F	(Middle)				e of Earliest	Tran	saction (I	Month	n/Day/Year)				below)	(give titl	e	belo	er (specify w)	
(Street)	N N	МА	02116		_	4. If A	mendment,	Date	of Origina	al File	ed (Month/Da	ay/Year)			Form fi	iled by C	ne Repo	orting Per	Applicable Line) son porting Person	
(City)	(;	State)	(Zip)																	
			Table I - N			_			cquire	d, D					Owned					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					if any	xecution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquire Disposed Of (D) (Inst			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
	G: 1			00.0	-1/20				Code	v	Amount	(A) (D)	\dashv	Price	Transaction (Instr. 3 and	4)			See	
Common	Stock				21/20:				J ⁽¹⁾		8,500,0			(1)	3,109,7	704			footnotes(2)(3	
			Table I				ecurities alls, war								Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Νι	mount or umber of nares		Transa (Instr. 4	ction(s)			
Warrant (Right to Buy)	\$0.001	08/21/2024			J ⁽¹⁾		8,500,000		(4)		(4)	Common Stock	8,	,500,000	(1)	8,500	0,000	I	See footnotes ⁽²⁾	
(Last)	RELEY S	FREET, 18TH F	(Mid				-													
(City)	nd Address of	(State) Reporting Person*	(Zip))			-													
		Ithcare Fund																		
(Last) 200 BER	KELEY S	(First) ΓREET, 18TH F	(Mid LOOR	dle)																
(Street)	N	MA	021	16			-													
(City)		(State)	(Zip))																
	nd Address of nsky Pete	Reporting Person*																		
		(First) MANAGEMEN FREET, 18TH F		dle)																

(City)	(State)	(Zip)	(Zip)			
1. Name and Addr Shah Rajeev	ess of Reporting Perso M.	1*				
(Last)	(First)	(Middle)				
C/O RA CAPI	ΓAL MANAGEME	NT, L.P.				
200 BERKELE	EY STREET, 18TH	FLOOR				
(Street)						
BOSTON	MA	02116				
(City)	(State)	(Zip)				

Explanation of Responses:

- 1. RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, on a 1:1 basis, 8,500,000 shares of the Issuer's Common Stock for an equal number of prefunded warrants, each to purchase one share of the Issuer's Common Stock at an exercise price of \$0.001 per share (each a "Pre-Funded Warrant").
- 2. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- 3. Held directly by the Fund.
- 4. The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.
/s/ /s/ Peter Kolchinsky, individually
/s/ Rajeev Shah, individually
** Signature of Reporting Person

08/23/2024

08/23/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.